Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00924820

A Pilot Study of Bevacizumab for Neoplastic Meningitis

A Pilot Study of Systemically Administered Bevacizumab in Patients With Neoplastic Meningitis (NM)

Sponsor: Genentech, Inc.

Interventions Bevacizumab

Updated 6 times since 2017 Last updated: Dec 30, 2020 Started: Jun 30, 2009 Primary completion: Sep 30, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Neoplastic Meningitis, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States